Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy
{{output}}
Pazopanib, which is being developed by GlaxoSmithKline plc, is an oral, second-generation multi-targeted tyrosine kinase inhibitor that targets VEGFR, platelet-derived growth factor receptor and c-kit, key proteins responsible for tumor growth and survival. Pa... ...
